AXCELLA HEALTH INC.

(AXLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
1.6(c) 1.7(c) 1.74(c) 1.73(c) 1.6(c) Last
20 275 11 720 15 086 10 890 24 352 Volume
+3.90% +6.25% +2.35% -0.57% -7.51% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -77,3 M - -
Net Debt 2022 23,3 M - -
P/E ratio 2022 -1,01x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -89,7 M - -
Net Debt 2023 123 M - -
P/E ratio 2023 -1,18x
Yield 2023 -
Capitalization 84,1 M 84,1 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 59
Free-Float 76,3%
More Financials
Company
Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Company’s product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting multiple biological pathways. AXA1665 is being developed as a product candidate... 
Sector
Biotechnology & Medical Research
Calendar
05/24 | 02:30pmPresentation
More about the company
Ratings of Axcella Health Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about AXCELLA HEALTH INC.
05/19Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
BU
05/09Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept
MT
05/05AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
05/05Axcella Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05Earnings Flash (AXLA) AXCELLA THERAPEUTICS Reports Q1 Loss $-0.46
MT
05/05Axcella Reports First Quarter Financial Results and Provides Business Update
BU
04/13Abbvie Vice Chairman Severino Departs for Flagship Pioneering
DJ
03/31SVB Leerink Trims Axcella Health's Price Target to $9 From $10, Maintains Outperform Ra..
MT
03/31Wedbush Trims Axcella Health's Price Target to $10 From $11, Keeps Outperform Rating
MT
03/30AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
03/30Axcella Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/30AXCELLA HEALTH : Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results ..
PU
03/30TRANSCRIPT : Axcella Health Inc., Q4 2021 Earnings Call, Mar 30, 2022
CI
03/30Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
BU
03/30Axcella Health Inc. Auditor Raises 'Going Concern' Doubt
CI
More news
News in other languages on AXCELLA HEALTH INC.
05/05Axcella Health Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 202..
03/30Axcella Health Inc. annonce ses résultats pour l'année complète se terminant le 31 déce..
03/30Axcella Health Inc. Le vérificateur remet en question la continuité de l'exploitation.
03/18Axcella Health Inc. annonce des changements de direction
03/16L'histoire montre que les actions peuvent résister au cycle de hausse des taux
More news
Analyst Recommendations on AXCELLA HEALTH INC.
More recommendations
Chart AXCELLA HEALTH INC.
Duration : Period :
Axcella Health Inc. Technical Analysis Chart | AXLA | US05454B1052 | MarketScreener
Technical analysis trends AXCELLA HEALTH INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,60 $
Average target price 11,50 $
Spread / Average Target 619%
EPS Revisions
Managers and Directors
William R. Hinshaw President, Chief Executive Officer & Director
Robert W. Crane Chief Financial Officer & Senior Vice President
David R. Epstein Chairman
Tony Tramontin Chief Scientific Officer, Senior VP-R&D
Alison Schecter President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AXCELLA HEALTH INC.-17.22%91
GILEAD SCIENCES, INC.-11.38%79 850
REGENERON PHARMACEUTICALS, INC.8.63%73 473
VERTEX PHARMACEUTICALS22.26%68 632
WUXI APPTEC CO., LTD.-22.20%42 378
BIONTECH SE-36.69%39 666